Boris Pasche, President and CEO at Karmanos Cancer Institute, Chair Department of Oncology at Wayne State University, shared a post on LinkedIn:
“Congratulations to Drs. Choucair and Azmi, along with their collaborators, on the publication of one of the most detailed reviews of KRAS as a therapeutic target in cancer.
It has long been established that mutated KRAS is a key driver of cancer. Recent advancements in targeting KRAS, including the significant contributions from Dr. Azmi’s group, are beginning to reveal the therapeutic potential of this innovative approach.”
Title: Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Authors: Khalil Choucair, Hafsa Imtiaz, Md Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A. Philip, Bassel El-Rayes, Boris C. Pasche, and Asfar S. Azmi
You can read the Full Article in Signal Transduction and Targeted Therapy.
More posts featuring Boris Pasche.